New York, Feb 12, 2026, 19:30 EST — After-hours
- Vertex shares ticked up in after-hours trading as the company rolled out its 2026 revenue guidance with its fourth-quarter results.
- Investors are tracking if the newer products will actually widen growth outside of the cystic fibrosis drug lineup.
- Top of mind right now: a kidney-disease initiative and how quickly fresh launches are coming through.
Vertex Pharmaceuticals (VRTX.O) ticked up 0.7% to $465.02 in Thursday’s after-hours action, following its release of quarterly numbers and a fresh 2026 revenue outlook. Earlier, the shares moved in a range from $451.17 to $469.80.
Numbers are front and center for Vertex these days, as the company aims to show it can push growth even with its cystic fibrosis business already sizable—and not so easy to accelerate. Investors want more than updates on existing winners; they’re asking for sharper insight into what’s ahead.
Things get tricky from here. Gene therapy launches hinge on coordinating treatment centers and patient schedules, and that new pain medication? Uptake relies on shifting both payer policies and doctor routines, prescription by prescription.
Vertex is projecting 2026 revenue in the $12.95 billion to $13.1 billion range — almost exactly matching the $13.02 billion consensus from analysts polled by LSEG. At least $500 million of that is slated to come from products outside cystic fibrosis. Casgevy infusions are expected to increase, and the company cited momentum from Journavx, its non-opioid pain medication, which tallied over 550,000 prescriptions by the end of 2025 and now has coverage with all three major pharmacy benefit managers. For the fourth quarter, revenue climbed 10% to $3.19 billion. Adjusted earnings came in at $5.03 per share, just missing estimates. Vertex also flagged interim data for its kidney-disease program povetacicept, anticipated in the first half of 2026, and noted it’s deploying a priority review voucher to accelerate FDA review. 1
Chief Executive Reshma Kewalramani described 2025 as a year marked by “strong revenue growth, commercial diversification, and pipeline advancement.” Looking ahead to 2026, Kewalramani pointed to execution—both in the cystic fibrosis franchise and in fresh launches. Vertex posted GAAP net income of roughly $1.2 billion for the quarter and wrapped up 2025 holding $12.3 billion in cash, cash equivalents, and marketable securities, per the company’s filing. 2
The cystic fibrosis business continues to carry the bulk of the weight. Everything else? Traders mostly see it as incremental updates. For the immediate future, Casgevy and Journavx are the benchmarks to watch.
Friday’s session is set to reveal if investors focus on the guidance range or latch onto the small adjusted earnings miss. The key early sign: does the market buy into non-CF revenue scaling fast enough to count in 2026?
Still, it’s easy for things to slip off track. Gene therapy revenue jumps around depending on patient starts in a given quarter, while even widespread payer coverage doesn’t guarantee consistent scripts for a just-launched pain drug. Delays in kidney-disease results, meanwhile, would mean investors have to wait longer for a catalyst they’re already counting on.
Now, investors zero in on a few things: timing, specifics—how Journavx adoption is tracking, how Casgevy infusion numbers are looking. They’re also watching to see if Vertex follows through on its timeline for interim povetacicept results and keeps its U.S. accelerated-approval filing on track for the first half of 2026.
